Amarillo National Bank Has $1.05 Million Holdings in Zoetis Inc. (NYSE:ZTS)

Amarillo National Bank cut its holdings in shares of Zoetis Inc. (NYSE:ZTSGet Rating) by 2.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,092 shares of the company’s stock after selling 122 shares during the quarter. Amarillo National Bank’s holdings in Zoetis were worth $1,047,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Horizon Investments LLC raised its stake in shares of Zoetis by 5.5% in the fourth quarter. Horizon Investments LLC now owns 9,113 shares of the company’s stock valued at $2,220,000 after purchasing an additional 477 shares in the last quarter. Resources Management Corp CT ADV raised its stake in shares of Zoetis by 18.7% in the first quarter. Resources Management Corp CT ADV now owns 3,112 shares of the company’s stock valued at $587,000 after purchasing an additional 491 shares in the last quarter. Raymond James Financial Services Advisors Inc. raised its stake in shares of Zoetis by 4.5% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 151,858 shares of the company’s stock valued at $28,643,000 after purchasing an additional 6,593 shares in the last quarter. Revolve Wealth Partners LLC raised its stake in shares of Zoetis by 6.3% in the first quarter. Revolve Wealth Partners LLC now owns 1,153 shares of the company’s stock valued at $217,000 after purchasing an additional 68 shares in the last quarter. Finally, Elk River Wealth Management LLC raised its stake in shares of Zoetis by 22.6% in the first quarter. Elk River Wealth Management LLC now owns 30,672 shares of the company’s stock valued at $5,784,000 after purchasing an additional 5,651 shares in the last quarter. 91.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 4,334 shares of the stock in a transaction on Monday, June 27th. The stock was sold at an average price of $175.00, for a total transaction of $758,450.00. Following the sale, the executive vice president now owns 23,687 shares in the company, valued at $4,145,225. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Kristin C. Peck sold 311 shares of the firm’s stock in a transaction dated Thursday, July 7th. The stock was sold at an average price of $180.00, for a total value of $55,980.00. Following the transaction, the chief executive officer now owns 39,743 shares in the company, valued at $7,153,740. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Roxanne Lagano sold 4,334 shares of the firm’s stock in a transaction dated Monday, June 27th. The shares were sold at an average price of $175.00, for a total value of $758,450.00. Following the completion of the transaction, the executive vice president now owns 23,687 shares in the company, valued at approximately $4,145,225. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 16,501 shares of company stock worth $2,949,073. Insiders own 0.12% of the company’s stock.

Zoetis Price Performance

Shares of ZTS stock traded down $0.43 during trading hours on Friday, hitting $149.03. 52,655 shares of the company’s stock were exchanged, compared to its average volume of 1,780,199. The stock’s 50-day moving average is $167.61 and its 200-day moving average is $173.54. The company has a debt-to-equity ratio of 1.14, a current ratio of 2.18 and a quick ratio of 1.46. The stock has a market cap of $69.77 billion, a price-to-earnings ratio of 33.71, a price-to-earnings-growth ratio of 2.64 and a beta of 0.77. Zoetis Inc. has a 52 week low of $148.96 and a 52 week high of $249.27.

Zoetis (NYSE:ZTSGet Rating) last announced its earnings results on Thursday, August 4th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.22 by ($0.02). The business had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.03 billion. Zoetis had a return on equity of 49.03% and a net margin of 26.14%. Zoetis’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.19 EPS. As a group, research analysts forecast that Zoetis Inc. will post 5.01 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on ZTS. StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Stifel Nicolaus cut their target price on Zoetis from $275.00 to $225.00 and set a “buy” rating for the company in a research note on Friday, June 24th. Piper Sandler started coverage on Zoetis in a research report on Monday, July 11th. They issued an “overweight” rating and a $205.00 price target on the stock. William Blair reiterated an “outperform” rating on shares of Zoetis in a research report on Friday, August 5th. Finally, The Goldman Sachs Group lowered their price target on Zoetis from $208.00 to $202.00 and set a “buy” rating on the stock in a research report on Thursday, July 21st. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $224.00.

Zoetis Profile

(Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Read More

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSGet Rating).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.